The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma.
J. Hansson
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Expert Testimony - Merck
S. Aamdal
Consultant or Advisory Role - Schering-Plough (B,U)
Other Remuneration - Schering-Plough
L. Bastholt
Consultant or Advisory Role - Schering-Plough
Other Remuneration - Schering-Plough
M. Hernberg
Consultant or Advisory Role - Abbott Laboratories; Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb; Merck; Roche
Research Funding - Schering-Plough
Other Remuneration - Schering-Plough
B. Nilsson
Other Remuneration - Schering-Plough (B)
U. K. Stierner
No relevant relationships to disclose
H. von der Maase
Other Remuneration - Schering-Plough
Y. Brandberg
Other Remuneration - Schering-Plough